OverviewSuggest Edit

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Its proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery. The Company's lead product candidate, Furoscix, consists of a novel formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
TypePublic
Founded2014
HQBurlington, MA, US
Websitescpharmaceuticals.com

Latest Updates

Employees (est.) (Feb 2019)27
Share Price (Sept 2021)$6.8(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at scPharmaceuticals

John H. Tucker

John H. Tucker

President, Chief Executive Officer & Director
Minnie V. Baylor-Henry

Minnie V. Baylor-Henry

Director
Mike Hassman

Mike Hassman

Senior Vice President, Technical Operations
Mette Kirstine Agger

Mette Kirstine Agger

Director
Rachael Nokes

Rachael Nokes

Senior Vice President, Finance
John Mohr

John Mohr

Senior Vice President, Clinical Development and Medical Affairs
Show more

scPharmaceuticals Office Locations

scPharmaceuticals has an office in Burlington
Burlington, MA, US (HQ)
2400 District Ave #310
Show all (1)

scPharmaceuticals Financials and Metrics

scPharmaceuticals Revenue

USD

Net income (Q1, 2021)

(7.1m)

EBIT (Q1, 2021)

(6.7m)

Market capitalization (23-Sept-2021)

189.8m

Closing stock price (23-Sept-2021)

6.8

Cash (31-Mar-2021)

75.8m

EV

133.4m
scPharmaceuticals's current market capitalization is $189.8 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

13.7m8.3m11.8m

R&D expense

15.9m24.6m18.1m

Operating expense total

29.7m32.9m29.9m

Depreciation and amortization

38.0k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

4.7m5.0m1.9m2.3m1.8m2.0m2.5m2.5m2.7m

R&D expense

4.0m4.9m3.9m6.5m5.5m4.3m4.1m5.1m4.0m

Operating expense total

8.7m9.9m5.8m8.8m7.3m6.3m6.6m7.7m6.7m

Depreciation and amortization

10.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

89.5m72.6m71.8m

Prepaid Expenses

1.8m2.6m2.6m

Current Assets

91.9m75.6m107.8m

PP&E

164.0k127.0k93.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(29.4m)(33.0m)(32.2m)

Depreciation and Amortization

38.0k37.0k34.0k

Accounts Payable

(1.4m)965.0k1.2m

Cash From Operating Activities

(28.8m)(30.4m)(27.7m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(8.7m)(18.6m)(24.3m)(8.7m)(16.0m)(22.2m)(7.1m)(15.4m)(7.1m)

Depreciation and Amortization

10.0k19.0k29.0k10.0k19.0k29.0k8.0k17.0k8.0k

Accounts Payable

(432.0k)179.0k(926.0k)2.1m4.8m3.9m(685.0k)343.0k(2.2m)

Cash From Operating Activities

(9.1m)(17.5m)(23.0m)(6.1m)(10.0m)(15.6m)(7.7m)(13.7m)(8.6m)
USDQ1, 2018

Financial Leverage

1.2 x
Show all financial metrics

scPharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

scPharmaceuticals Online and Social Media Presence

Embed Graph

scPharmaceuticals News and Updates

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021

Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today a…

scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4

scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study

Reduced average 30-day heart failure related costs by $17,753 (p<0.0001) per study subject in FUROSCIX® arm compared to historically matched comparators

scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

BURLINGTON, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today ann…
Show more

scPharmaceuticals Blogs

scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA

No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million , sufficient to fund operations through potential FUROSCIX® approval and launch and into 2023 BURLINGTON, Mass. , Feb.

scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference

scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference Content Import Thu, 02/11/2021 - 08:02 scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference 02/11/21 This release is a backfill from a …

scPharmaceuticals Provides Business Update

BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 8, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update

scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration

FUROSCIX ® is currently under development for the treatment of congestion due to fluid overload in adult patients with worsening heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization Call on Tuesday, September 29, 2020 at 11am Eastern Time

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 3, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update Content Import Thu, 08/13/2020 - 07:00 scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update 08/13/20 This release is …
Show more

scPharmaceuticals Frequently Asked Questions

  • When was scPharmaceuticals founded?

    scPharmaceuticals was founded in 2014.

  • Who are scPharmaceuticals key executives?

    scPharmaceuticals's key executives are John H. Tucker, Minnie V. Baylor-Henry and Mike Hassman.

  • How many employees does scPharmaceuticals have?

    scPharmaceuticals has 27 employees.

  • Who are scPharmaceuticals competitors?

    Competitors of scPharmaceuticals include Biosearch Life, Cue Biopharma and ANI Pharmaceuticals.

  • Where is scPharmaceuticals headquarters?

    scPharmaceuticals headquarters is located at 2400 District Ave #310, Burlington.

  • Where are scPharmaceuticals offices?

    scPharmaceuticals has an office in Burlington.

  • How many offices does scPharmaceuticals have?

    scPharmaceuticals has 1 office.